Journal
REGENERATIVE MEDICINE
Volume 10, Issue 5, Pages 591-609Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/rme.15.29
Keywords
allogeneic cell therapy manufacture; bioprocess economics; centrifugation; downstream processing; filling; tangential flow filtration
Categories
Funding
- Technology Strategy Board (UK)
- Lonza
- Engineering and Physical Sciences Research Council [EP/I033270/1] Funding Source: researchfish
- EPSRC [EP/I033270/1] Funding Source: UKRI
Ask authors/readers for more resources
Aim: To develop a decisional tool to identify the most cost effective process flowsheets for allogeneic cell therapies across a range of production scales. Materials & methods: A bioprocess economics and optimization tool was built to assess competing cell expansion and downstream processing (DSP) technologies. Results: Tangential flow filtration was generally more cost-effective for the lower cells/lot achieved in planar technologies and fluidized bed centrifugation became the only feasible option for handling large bioreactor outputs. DSP bottlenecks were observed at large commercial lot sizes requiring multiple large bioreactors. The DSP contribution to the cost of goods/dose ranged between 20-55%, and 50-80% for planar and bioreactor flowsheets, respectively. Conclusion: This analysis can facilitate early decision-making during process development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available